ICI drugs act by blocking inhibitory receptors, cytotoxic T lymphocyte antigen-4 (CTLA-4), and programmed death-1 (PD-1) on T lymphocytes and their interaction with their corresponding ligands (CD80/86 and PD-L1/-L2, respectively) on tumor cells. The gene discussed is CTLA4; the disease is neoplasm.